China's NMPA has approved a rare-disease therapy for commercial sales to treat narcolepsy type 1 in individuals aged 16 and older. The unnamed drug previously received fast-track status in the US and orphan-drug designation in Japan and the EU, indicating international recognition for its importance.
South Korea's biopharmaceutical exports are projected to reach a record high in the first half of this year, with an estimated $4.5 billion in shipments, a 15.3% increase. The sector's growth is driven by recombinant protein drugs, with key export markets including Switzerland, the United States, and Hungary.
South Korea's biopharmaceutical exports reached a record $4.5 billion in the first half of 2024, a 15.3% increase year-on-year. This surge represents 86.5% of total pharmaceutical exports, with significant growth in US and European markets. Projections indicate a new annual record if the upward trend continues.
Royalty Pharma, the world's largest biopharmaceutical royalty buyer, established its first Asia-Pacific base in Hong Kong. This move aims to capitalize on record Chinese biotech out-licensing deals and offers an alternative financing method amidst US investment restrictions and geopolitical uncertainties.
The US Department of Defense added WuXi AppTec to its list of Chinese military companies. Analysts predict minimal impact on the company and the broader pharma sector due to cost efficiencies and ongoing collaboration.
SEOUL, May 6 (Yonhap) -- Celltrion Inc., a major South Korean biopharmaceutical ...
Servier a mené «avec succès» son offre publique d’achat visant la totalité des actions de l’entreprise biopharmaceutique américaine Day One Biopharmaceuticals.
